The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

SOUTH SAN FRANCISCO, CA, USA I April 01, 2025 I TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage ...

Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis ...

FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...

SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Approximately 80% of individuals who receive immune checkpoint inhibitors for advanced cancer do not respond to therapy, according to results of a cross-sectional analysis.The number of FDA-approved ...

Pembrolizumab and XL888 in advanced CRC showed manageable safety, though limited responses and potential immunomodulatory ...